CSE: HAVN
OTC: HAVLF
FRA: 5NP
Get Notified
Edit Content
Main Menu
CSE: HAVN
OTC: HAVLF
FRA: 5NP

treatment-resistant depression

Studies show psilocybin therapy has potential for anorexia nervosa and severe treatment-resistant depression

Leave a Comment / Education, Health & Performance, Psychedelics / By

Positive Early Signals Seen in Two Investigator-Initiated Studies Presented at the Society of Biological Psychiatry Annual Meeting in New Orleans COMPASS Pathways (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that positive data two investigator-initiated studies demonstrating the potential of COMP360 psilocybin therapy in anorexia …

Studies show psilocybin therapy has potential for anorexia nervosa and severe treatment-resistant depression Read More »

Monash University-Led Team Receives Funding for Psychedelic Psychotherapy in Treatment-Resistant Depression

Leave a Comment / Education, Psychedelics / By

The Medical Research Future Fund Clinical Trials Activity Initiative has awarded $2.7M for Innovative Therapies for Mental Illness to a Monash University-led team, to evaluate the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression. Major Depressive Disorder (MDD) is, sadly, common, and results in the greatest global burden of disease. Although there are established treatments for …

Monash University-Led Team Receives Funding for Psychedelic Psychotherapy in Treatment-Resistant Depression Read More »